Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

The present study is designed to assess anatomical and functional outcomes following a
single intravitreal injection of ocriplasmin 0.125mg in subjects with symptomatic
vitreomacular adhesion (VMA)/ (VMT) including macular hole.

Inclusion Criteria:

- Subjects 18 years of age or older and of either gender

- Presence of vitreomacular adhesion

- Best corrected visual acuity (BCVA) of 20/32 or worse in study eye

- BCVA of 20/800 or better in the non-study eye

Exclusion Criteria:

- History or current evidence of proliferative retinopathy, exudative age-related
macular degeneration (AMD) or retinal vein occlusion in the study eye

- Any vitreous hemorrhage or any other vitreous opacification which precludes the
visualization of the posterior pole by visual inspection OR adequate assessment of
the macula by spectral-domain optical coherence tomography (SD-OCT) in the study eye

- Macular hole of > 400 µm diameter in the study eye

- Presence of epiretinal membrane (ERM)

- Aphakia in the study eye

- High myopia (more than 8D) in study eye

- History of rhegmatogenous retinal detachment in either eye

- History of vitrectomy in the study eye

- Previous participation in this trial or prior administration of ocriplasmin in the
study eye